Computed tomography scans do not improve the predictive power of 1996 national cancer institute-sponsored working group chronic lymphocytic leukemia response criteria

被引:14
作者
Blum, Kristie A. [1 ]
Young, Donn
Broering, Sarah
Lucas, Margaret S.
Fischer, Beth
Lin, Thomas S.
Grever, Michael R.
Byrd, John C.
机构
[1] Ohio State Univ, Coll Pharm, Div Hematol Oncol, Dept Internal Med, Columbus, OH 43210 USA
关键词
D O I
10.1200/JCO.2007.12.1152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose National Cancer Institute-sponsored Working Group (NCI-WG) response criteria for chronic lymphocytic leukemia (CLL) rely on physical examination, blood, and bone marrow evaluations. The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria. Patients and Methods In a retrospective review of 82 CLL patients treated at the Ohio State University (Columbus, OH), we compared CT assessed response using non-Hodgkin's lymphoma (NHL) response definitions with NCI-WG response. Results Responses by NCI-WG criteria included five complete responses (CRs), 32 partial responses (PRs), 21 patients with stable disease (SD), 17 patients with progressive disease (PD), and seven patients not assessable (NA). Responses by NHL-CT criteria included three CRs, 12 unconfirmed CRs (CRus), 16 PRs, 26 with SD, four with PD, and 21 NA. Using NCI-WG criteria, progression-free survival (PFS) was 27.3 months for CR and 11.4 months for PR. With NHL-CT criteria, PFS was 18.4 months for CR, 11.7 months for CRu, and 14.5 months for PR. In multivariate analysis, both NCI-WG and NHL-CT response correlated with PFS (P = .009 and. 001, respectively). Conclusion Current NCI-WG CLL response criteria are a significant predictor of PFS in previously treated CLL patients, with no additional benefit from the inclusion of CT scans. Although retrospective, these results highlight the importance of prospective validation of CT scans before routine inclusion in CLL response criteria.
引用
收藏
页码:5624 / 5629
页数:6
相关论文
共 21 条
[1]  
BOSCH F, 2006, P AM SOC HEM, V108, P802
[2]   Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].
Byrd, JC ;
Peterson, BL ;
Morrison, VA ;
Park, K ;
Jacobson, R ;
Hoke, E ;
Vardiman, JW ;
Rai, K ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2003, 101 (01) :6-14
[3]   Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].
Byrd, JC ;
Rai, K ;
Peterson, BL ;
Appelbaum, FR ;
Morrison, VA ;
Kolitz, JE ;
Shepherd, L ;
Hines, JD ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2005, 105 (01) :49-53
[4]  
BYRD JC, 2004, P AM SOC HEM, V104, P686
[5]   Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].
Byrd, John C. ;
Lin, Thomas S. ;
Dalton, James T. ;
Wu, Di ;
Phelps, Mitch A. ;
Fischer, Beth ;
Moran, Mollie ;
Blum, Kristie A. ;
Rovin, Brad ;
Brooker-McEldowney, Michelle ;
Broering, Sarah ;
Schaaf, Larry J. ;
Johnson, Amy J. ;
Lucas, David M. ;
Heerema, Nyla A. ;
Lozanski, Gerard ;
Young, Donn C. ;
Suarez, Jose-Ramon ;
Colevas, A. Dimitrios ;
Grever, Michael R. .
BLOOD, 2007, 109 (02) :399-404
[6]  
CHANAN K, 2006, J CLIN ONCOL, V24, P5343
[7]  
CHERUKURI A, 2005, P AM SOC HEM, V832, P12
[8]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[9]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[10]   Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia [J].
Eichhorst, BF ;
Busch, R ;
Hopfinger, G ;
Pasold, R ;
Hensel, M ;
Steinbrecher, C ;
Siehl, S ;
Jäger, U ;
Bergmann, M ;
Stilgenbauer, S ;
Schweighofer, C ;
Wendtner, CM ;
Döhner, H ;
Brittinger, G ;
Emmerich, B ;
Hallek, M .
BLOOD, 2006, 107 (03) :885-891